SAR

Sareum Holdings PLC

Health Care First-pass screen £28m

310/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 35

Valuation 25% 30

Downside protection 15% 40

First-pass take

Early-stage biotech with zero AI exposure, no revenue, and Phase 1 data only. Positive safety/PK data for SDC-1801 de-risks somewhat, but company requires capital raises every ~18 months; misaligned with AI/defensiveness criteria.

Flags

loss-makingpre-revenuebiotechearly-stagecapital-intensiveno-valuation-data